The Societal Value of Broader Access to Antiobesity Medications.
Mina KabiriAlison Sexton WardAbhilasha RamasamyEmma van EijndhovenRahul GangulyBrian Gabriel SmolarzTracy ZvenyachDana P GoldmanJames R BaumgardnerPublished in: Obesity (Silver Spring, Md.) (2019)
This study suggests that AOM provide substantial gains to patients and society. Policies promoting broader clinical access to and use of AOM warrant consideration to reach national goals to reduce obesity.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- public health
- metabolic syndrome
- insulin resistance
- peritoneal dialysis
- weight loss
- prognostic factors
- quality improvement
- patient reported outcomes
- adipose tissue
- body mass index
- weight gain
- high fat diet induced
- global health
- patient reported